EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY

Equipe constitutive du CERPOP, UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier
Cécile CONTE •  chercheure



2023
  1. de Germay S, Conte C, Micallef J, Bouquet E, Chouchana L, Lafaurie M, Pariente A; au nom du groupe de pharmaco-épidémiologie de la Société Française de Pharmacologie et de Thérapeutique (SFPT). Réalisation d’études pharmacoépidémiologiques à partir du système national des données de santé (SNDS) : application des recommandations dans la pratique [Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice]. Therapie. 2023 Jan 29:S0040-5957(23)00027-6. French. doi: 10.1016/j.therap.2023.01.010. Epub ahead of print.
  2. Gosselin L, Vilcu AM, Souty C, Steichen O, Launay T, Conte C, Saint-Salvi B, Turbelin C, Sarazin M, Blanchon T, Hanslik T, Lapeyre-Mestre M, Rossignol L. Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database. Eur J Clin Pharmacol. 2023 Jul;79(7):937-945. doi: 10.1007/s00228-023-03501-8.
  3. Joly M, Conte C, Cazanave C, Le Moing V, Tattevin P, Delobel P, Sommet A, Martin-Blondel G. Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions. Brain. 2023 Jan 5;146(1):349-358. doi: 10.1093/brain/awac237.
  4. Zelmat Y, Conte C, Noize P, Vabre C, Pajiep M, Lafaurie M, Lapeyre-Mestre M, Despas F. Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study. Br J Clin Pharmacol. 2023 Apr;89(4):1338-1348. doi: 10.1111/bcp.15576.
2022
  • Conte C, Vayr F, Pajiep MC, Despas F, Huguet F, Mestre ML, Gauthier M, Herin F. Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study. Support Care Cancer. 2022 Jun;30(6):5431-5440. doi: 10.1007/s00520-022-06968-w.
     
  • Paternoster M, Steichen O, Lapeyre-Mestre M, Blanchon T, Rossignol L, Vilcu AM, Launay T, Sarazin M, Bagheri H, Conte C, Turbelin C, Hanslik T, Souty C. Risk of Bleeding Associated With Nonsteroidal Anti-inflammatory Drug Use in Patients Exposed to Antithrombotic Therapy: A Case-Crossover Study. J Clin Pharmacol. 2022 May;62(5):636-645. doi: 10.1002/jcph.2003.
     
  • Strumia M, Perrin ML, Patras de Compaigno E, Conte C, Montastruc F, Lapeyre-Mestre M, Sibaud V, Despas F. Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®. Therapie. 2022 Mar-Apr;77(2):219-227. doi: 10.1016/j.therap.2021.12.006
2021
  • Pajiep M, Conte C, Huguet F, Gauthier M, Despas F, Lapeyre-Mestre M. Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France. Front Oncol. 2021 Sep 30;11:675609. doi: 10.3389/fonc.2021.675609.
2020
  • de Germay S, Conte C, Rascol O, Montastruc JL, Lapeyre-Mestre M. β-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study. CNS Drugs. 2020 Jul;34(7):763-772. doi: 10.1007/s40263-020-00736-2.
     
  • Gauthier M, Conte C, Palmaro A, Patras De Campaigno E, De Barros S, Huguet F, Laurent G, Lapeyre-Mestre M, Despas F. Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population-based study in France. Fundam Clin Pharmacol. 2020 Oct;34(5):612-622. doi: 10.1111/fcp.12544.
     
  • Mounié M, Costa N, Conte C, Petiot D, Fabre D, Despas F, Lapeyre-Mestre M, Laurent G, Savy N, Molinier L. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France. J Med Econ. 2020 Mar;23(3):235-242. doi: 10.1080/13696998.2019.1702990.